	Please type a plus sign (	+) inside this box Π h 09/30/2000. OMB 0651-00.	+ 31 Patent and Tradem	ark Office: U.S. DEPART	MENT OF	PTO/SB/21 (6-99)		
/9	Under the Paperwork Re	duction Act of 1995, no perso	ns are required to resp	oond to a collection of info	rmation unle	ess it displays a valid OMB control number.		
′	UL 2 3 2004 TRANSMITTAL			Application Num	ber	09/903,640		
ره.				Filing Date		July 11, 2001		
Ž,	FORM  (to be used for all correspondence after initial filing)			First Named Inve	ntor	Avi Ashkenazi, et al.		
	(to be used for all correspondence after initial filing)			Group/Art Unit		1636		
				Examiner Name		Konstantina T. KATCHEVES		
	Total Number of P	ages in This Submission	308 pgs.	Attorney Docket N	lumber	39780-1618P2C48		
	ENCLOSURES (check all that apply)							
	Fee Transmittal Form		Assignment Papers (for an Application)		After Allowance Communication to Group  Appeal Communication to Board			
	Fee Attached  Amendment / Response		Drawing(s)  Licensing-related Papers		of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)			
	After Final			Petition Routing Slip (PTO/SB/69) and Accompanying Petition		Proprietary Information		
	Version with Markings Showing Changes		Petition to Convert to a Provisional Application		Status Letter			
•	Affidavits/declaration(s)		Power of Attorney, Revocation Change of Correspondence Address		Additional Enclosure(s) (please identify below):			
·	Extension of Time Request  Information Disclosure Statement		Terminal Disclaimer		stamped return postcard; PTO Form 1449;			
	I <u> </u>		Small E	Small Entity Statement		copies of 9 cited reference		
	Document(s)	Certified Copy of Priority Document(s)		for Refund				
	Response to Missing Parts/ Incomplete Application		Remarks					
	Response to Missing Parts under 37 CFR 1.52 or 1.53		AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER.					
	SIGNATURE OF APPLICANT, ATTORNEY OR AGENT							
	Firm or Individual name	Daphne Reddy, Reg. No HELLER EHRMAN W		IFFÉ LLP				
	Signature Saphue Reddy							
	Date July 23, 2004			Customer Numb	er: 09	9157/35489		
CERTIFICATE OF MAILING								
	Addressee" service	hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date: July 23, 2004.						
	Typed or printed r					<del></del>		
	Signature	Sanas	Pulsi		Date	July 23, 2004		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time vil vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop \_\_; Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

OIPE COLLEGE

07.24.04

AS/1434

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date: July 23, 2004

[Express Mail Label EL 993 692 204 US]

Typed or printed name Sandra Puljic

Signature Date July 23, 2004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Avi Ashkenazi, et al.

Docket No.:

39780-1618P2C48

Serial No.:

09/903,640

Group Art Unit:

1636

Filing Date:

July 11, 2001

Examiner:

Konstantina T. KATCHEVES

For:

SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS

**ENCODING THE SAME** 

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on an attached Form PTO-1449 is information known to applicant(s). Each reference listed has been cited in a related patent application, US Serial No. 09/903,925 (claiming PRO 343 antibody); Our Ref. No. 39780-1618P2C49 and/or US Serial No. 09/909,320 (claiming PRO 343 nucleic acid); Our Ref. No. 39780-1618P2C80. A copy of each reference is provided herewith. Applicants submit these documents to ensure that all references are of record and considered in all related applications. Applicants respectfully request the Examiner to acknowledge consideration of the currently submitted references by initialing and returning form PTO-1449 in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.



	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):						
		(1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  OR					
		(2)	It is being filed within 3 month OR	s of entry of a national stage			
				date of the first Office Action on the merits			
				ng of a first Office Action after the filing of a on under § 1.114.			
	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:						
		a certification as specified in §1.97(e) is provided below; or					
		a fee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.					
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:						
	A.	a certification as specified in §1.97(e) is completed below; and					
	B.	a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and					
	C.	a fee of \$180.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.					
	<i>Fee Authorization.</i> The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. <u>08-1641</u> ( <u>Docket No. 39780-1618P2C48</u> ).						
				Respectfully submitted,			
Dated:	July 23,	2004		By: Kaphne Reddy Daphne Reddy Reg. No. 53,507			

HELLER EHRMAN WHITE & MCAULIFFE LLP

Customer No. 09157/35489

275 Middlefield Road

Menlo Park, CA 94025-3506

Telephone: (650) 324-7000/Facsimile: (650) 324-0638

JUL 2 3 2004 33

## AFTY. DOCKET NO.: **SERIAL NO.:** INFORMATION DISCLOSURE **STATEMENT** 09/903,640 39780-1618P2C48 APPLICANT: Avi Ashkenazi, et al. PTO-1449 FILING DATE: July 11, 2001 **GROUP: 1636** U.S. PATENT DOCUMENTS **EXAMINER'S** PATENT NO. **CLASS SUBCLASS** DATE NAME FILING DATE **INITIALS** 5,821,337 10/13/1998 Carter, P., et al. 530 387.3 FOREIGN PATENT DOCUMENTS TRANSLATION EXAMINER'S PATENT NO. DATE **CLASS SUBCLASS** COUNTRY **INITIALS** YES NO WO 98/36054 8/20/1998 **PCT** C12N 9/12 П OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Haynes, Paul A., et al., "Proteome analysis: Biological assay or data archive?", Electrophoresis, 19, 1998, pp 1862-1871 Konopka, James B., et al., "Variable expression of the translocated c-abl oncogene in Philadelphia-chromosome-positive Blymphoid cell lines from chronic myelogenous leukemia patients", Proc. Natl. Acad. Sci. USA, Vol 83, 1986, pp 4049-4052 Pennica, Diane, et al, "WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1-transformed cells and aberrantly expressed in human colon tumors", Proc. Natl. Acad. Sci. USA, Vol. 95, December 1998, pp 14717-14722 Accession No. AC003965, Direct Submission, Submitted: December 31, 1997, Ricke, D. O. et al. Accession No. AB010779, Direct Submission, Submitted: January 27, 1998, Yamaguchi et al. Accession No. AAA61698, WO 200031211-A1, Pub Date: June 2, 2000, Fuso Pharm. Ind. Ltd.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

**EXAMINER**